Myriad Genetics MYGN Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's operating lease right-of-use asset amortization?
- Myriad Genetics (MYGN) reported operating lease right-of-use asset amortization of $1M in Q1 2026.
- How has Myriad Genetics's operating lease right-of-use asset amortization changed year-over-year?
- Myriad Genetics's operating lease right-of-use asset amortization decreased by 64.3% year-over-year, from $2.8M to $1M.
- What is the long-term trend for Myriad Genetics's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Myriad Genetics's operating lease right-of-use asset amortization has grown at a -11.9% compound annual growth rate (CAGR), from $12.8M to $7.7M.